Cor­rect­ed: Ab­b­Vie, Ipsen end part­ner­ships with Ex­i­cure fol­low­ing set­backs, job cuts

Ex­i­cure and its two phar­ma­ceu­ti­cal part­ners have for­mal­ly stopped their work on their de­vel­op­ment part­ner­ships as the biotech winds up op­er­a­tions and seeks to sell …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER